FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2795688435> ?p ?o ?g. }

• W2795688435 abstract "The median survival of patients with HER2-positive metastatic breast cancer has more than doubled since the discovery of HER2-targeted treatments: it rose from less than 2 years in 2001 (prior introduction of trastuzumab) to more than 4 years in 2017. The initial generation of HER2-targeted therapies included trastuzumab with taxanes in the 1st line, followed by the addition of lapatinib and by a switch to another cytotoxic agent after progression. Results of CLEOPATRA, EMILIA and TH3RESA trials have changed this clinical practice. The current consensus includes horizontal dual blockade (trastuzumab+pertuzumab) with taxanes or vinorelbine in the 1st line, followed by trastuzumab-emtansine (T-DM1) in the 2nd line, with addition of lapatinib in the later lines of treatment. However, the fast and simultaneous development of new drugs led to a relative shortage of clinical evidence to support this sequence. Triple-positive breast cancers (TPBC), which express both hormonal receptors and HER2, constitute nearly half of HER2-positive cases. For these tumours, the current consensus is to add endocrine therapy after completion of cytotoxic treatment. Again, this consensus is not fully evidence-based. In view of the recent progress in treatment of oestrogen-receptor-positive breast cancers, a series of trials is evaluating addition of CDK4/6 inhibitors, aromatase inhibitors or fulvestrant to HER2-targeted and cytotoxic chemotherapy in TPBC patients. Despite the remarkable progress in treatment of HER2-positive breast cancer, metastatic disease is still incurable in the majority of patients. A wide range of novel therapies are under development to prevent and overcome resistance to current HER2-targeted agents. This review discusses pivotal clinical trials that have shaped current clinical practices, the current consensus recommendations and the new experimental treatments in metastatic HER2-positive breast cancer." @default.
• W2795688435 created "2018-04-13" @default.
• W2795688435 creator A5084311056 @default.
• W2795688435 date "2018-04-03" @default.
• W2795688435 modified "2023-10-14" @default.
• W2795688435 title "Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients" @default.
• W2795688435 cites W121353936 @default.
• W2795688435 cites W1464936406 @default.
• W2795688435 cites W1571186299 @default.
• W2795688435 cites W1573363574 @default.
• W2795688435 cites W1820767183 @default.
• W2795688435 cites W189635737 @default.
• W2795688435 cites W1961026612 @default.
• W2795688435 cites W1964808503 @default.
• W2795688435 cites W1976446970 @default.
• W2795688435 cites W1981701117 @default.
• W2795688435 cites W1981711832 @default.
• W2795688435 cites W1990097438 @default.
• W2795688435 cites W1991199800 @default.
• W2795688435 cites W1995242599 @default.
• W2795688435 cites W1996695017 @default.
• W2795688435 cites W1997381761 @default.
• W2795688435 cites W2005100930 @default.
• W2795688435 cites W2012784647 @default.
• W2795688435 cites W2013669698 @default.
• W2795688435 cites W2026251993 @default.
• W2795688435 cites W2029542561 @default.
• W2795688435 cites W2033292737 @default.
• W2795688435 cites W2034414538 @default.
• W2795688435 cites W2037690883 @default.
• W2795688435 cites W2037873158 @default.
• W2795688435 cites W2038451517 @default.
• W2795688435 cites W2039407184 @default.
• W2795688435 cites W2039792930 @default.
• W2795688435 cites W2040975353 @default.
• W2795688435 cites W2044702943 @default.
• W2795688435 cites W2045134790 @default.
• W2795688435 cites W2048272960 @default.
• W2795688435 cites W2051665090 @default.
• W2795688435 cites W2052292334 @default.
• W2795688435 cites W2059411043 @default.
• W2795688435 cites W2063376924 @default.
• W2795688435 cites W2063908296 @default.
• W2795688435 cites W2064086110 @default.
• W2795688435 cites W2064823103 @default.
• W2795688435 cites W2064839484 @default.
• W2795688435 cites W2073107785 @default.
• W2795688435 cites W2078074220 @default.
• W2795688435 cites W2094627540 @default.
• W2795688435 cites W2096721687 @default.
• W2795688435 cites W2097698108 @default.
• W2795688435 cites W2098953839 @default.
• W2795688435 cites W2100014422 @default.
• W2795688435 cites W2101299592 @default.
• W2795688435 cites W2101824720 @default.
• W2795688435 cites W2103808574 @default.
• W2795688435 cites W2106777108 @default.
• W2795688435 cites W2109176076 @default.
• W2795688435 cites W2110444464 @default.
• W2795688435 cites W2114101532 @default.
• W2795688435 cites W2115759102 @default.
• W2795688435 cites W2117538553 @default.
• W2795688435 cites W2118191456 @default.
• W2795688435 cites W2118371851 @default.
• W2795688435 cites W2118600577 @default.
• W2795688435 cites W2120627364 @default.
• W2795688435 cites W2121198752 @default.
• W2795688435 cites W2122080125 @default.
• W2795688435 cites W2124812632 @default.
• W2795688435 cites W2125401809 @default.
• W2795688435 cites W2127457632 @default.
• W2795688435 cites W2127714076 @default.
• W2795688435 cites W2128402413 @default.
• W2795688435 cites W2130019032 @default.
• W2795688435 cites W2130727852 @default.
• W2795688435 cites W2133503038 @default.
• W2795688435 cites W2134031795 @default.
• W2795688435 cites W2136488739 @default.
• W2795688435 cites W2136791645 @default.
• W2795688435 cites W2137086207 @default.
• W2795688435 cites W2137228442 @default.
• W2795688435 cites W2137743100 @default.
• W2795688435 cites W2139135964 @default.
• W2795688435 cites W2140055441 @default.
• W2795688435 cites W2141393790 @default.
• W2795688435 cites W2141546964 @default.
• W2795688435 cites W2141712412 @default.
• W2795688435 cites W2141777534 @default.
• W2795688435 cites W2142911989 @default.
• W2795688435 cites W2144686284 @default.
• W2795688435 cites W2146504901 @default.
• W2795688435 cites W2147761019 @default.
• W2795688435 cites W2148345265 @default.
• W2795688435 cites W2148479421 @default.
• W2795688435 cites W2148527073 @default.
• W2795688435 cites W2149707499 @default.
• W2795688435 cites W2152142449 @default.
• W2795688435 cites W2159427817 @default.
• W2795688435 cites W2159967578 @default.
• W2795688435 cites W2161708183 @default.

• next